D-0322-2020 Class III Terminated

Recalled by Sato Pharmaceutical Inc. — Torrance, CA

FDA drug recall D-0322-2020 was initiated by Sato Pharmaceutical Inc. on Oct 1, 2019 and is designated Class III. Reason for recall: Subpotent Drug The recall status is terminated (terminated Aug 18, 2020). Affected quantity: 21,864 units.

Recall details

Product Type
Drugs
Report Date
Nov 20, 2019
Initiation Date
Oct 1, 2019
Termination Date
Aug 18, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
21,864 units

Product description

Zentrip (meclizine Hydrochloride), 25 mg strips, 8-strips per box, Distributed by Sato Pharmaceutical INC. 20695 S. Western Ave., Suite 240 Torrence, CA 90501, NDC 49873-803-01. UPC 4987301603

Reason for recall

Subpotent Drug

Distribution pattern

Nationwide within the United States, Guam and Saipan

Code information

Lot #: TXWW, TXTW, Exp. date Dec 2019; AXPS, AXLS, AXBS AXNS, Exp. date Oct 2021; AXZL, AXAL, AXTL, AXWL, Exp. date Jun 2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0322-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0322-2020. Report a data issue: hello@regdatalab.com.